ZA200703888B - Anti-glypican 3 antibody having modified sugar chain - Google Patents

Anti-glypican 3 antibody having modified sugar chain

Info

Publication number: ZA200703888B
Authority: ZA; South Africa
Prior art keywords: glypican; antibody; sugar chain; modified sugar; modified
Prior art date: 2004-10-26

Application number

ZA200703888A

Other languages

English (en)

Inventor

Nakano Kiyotaka

Sugimoto Masamichi

Tanaka Megumi

Sugo Izumi

Ishiguro Takahiro

Iijima Shigeyuki

Original Assignee

Chugai Pharmaceutical Co Ltd

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2004-10-26

Filing date

2007-05-14

Publication date

2009-11-25

2007-05-14 Application filed by Chugai Pharmaceutical Co Ltd filed Critical Chugai Pharmaceutical Co Ltd

2009-11-25 Publication of ZA200703888B publication Critical patent/ZA200703888B/xx

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/303—Liver or Pancreas
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
- C07K2317/41—Glycosylation, sialylation, or fucosylation
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/72—Increased effector function due to an Fc-modification
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
- C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Organic Chemistry (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Genetics & Genomics (AREA)
Immunology (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Biochemistry (AREA)
Biophysics (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Molecular Biology (AREA)
Microbiology (AREA)
Biotechnology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Chemical Kinetics & Catalysis (AREA)
Cell Biology (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Gastroenterology & Hepatology (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
General Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
General Chemical & Material Sciences (AREA)
Physics & Mathematics (AREA)
Plant Pathology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Peptides Or Proteins (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Preparation Of Compounds By Using Micro-Organisms (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Saccharide Compounds (AREA)

ZA200703888A 2004-10-26 2007-05-14 Anti-glypican 3 antibody having modified sugar chain ZA200703888B (en)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
JP2004311356		2004-10-26

Publications (1)

Publication Number	Publication Date
ZA200703888B true ZA200703888B (en)	2009-11-25

Family

ID=36227980

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
ZA200703888A ZA200703888B (en)	2004-10-26	2007-05-14	Anti-glypican 3 antibody having modified sugar chain

Country Status (20)

Country	Link
US (2)	US7867734B2 (xx)
EP (1)	EP1816140A4 (xx)
JP (1)	JP4794457B2 (xx)
KR (1)	KR101296931B1 (xx)
CN (1)	CN101068836B (xx)
AU (1)	AU2005297772B2 (xx)
BR (1)	BRPI0518279A2 (xx)
CA (1)	CA2585196C (xx)
CR (1)	CR9151A (xx)
HK (1)	HK1110335A1 (xx)
IL (1)	IL182662A (xx)
MA (1)	MA29025B1 (xx)
MX (1)	MX2007004593A (xx)
NO (1)	NO20072366L (xx)
NZ (1)	NZ554940A (xx)
RU (1)	RU2451030C2 (xx)
TW (1)	TWI468514B (xx)
UA (1)	UA93488C2 (xx)
WO (1)	WO2006046751A1 (xx)
ZA (1)	ZA200703888B (xx)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
WO2004022597A1 (ja) *	2002-09-04	2004-03-18	Chugai Seiyaku Kabushiki Kaisha	Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
ES2348008T3 (es) *	2003-06-18	2010-11-26	Chugai Seiyaku Kabushiki Kaisha	Transportador de fucosa.
NZ579543A (en)	2004-07-09	2011-07-29	Chugai Pharmaceutical Co Ltd	Anti-glypican 3 antibody
PL1800693T3 (pl)	2004-08-24	2013-12-31	Chugai Pharmaceutical Co Ltd	Terapia adiuwantowa z zastosowaniem przeciwciała przeciw glipikanowi 3
EP1816140A4 (en) *	2004-10-26	2009-09-02	Chugai Pharmaceutical Co Ltd	ANTI-GLYPICAN ANTIBODY 3 MODIFIED SWEET CHAIN
US20070087005A1 (en) *	2005-10-14	2007-04-19	Lazar Gregory A	Anti-glypican-3 antibody
PT2178921E (pt)	2007-07-17	2016-03-23	Squibb & Sons Llc	Anticorpos monoclonais contra glipicano-3
MX369784B (es)	2007-09-26	2019-11-21	Chugai Pharmaceutical Co Ltd	Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
ES2394471T3 (es) *	2007-09-28	2013-02-01	Chugai Seiyaku Kabushiki Kaisha	Anticuerpo Anti-Glipicano 3 que tiene una cinética mejorada en plasma
CL2009000647A1 (es) *	2008-04-04	2010-06-04	Chugai Pharmaceutical Co Ltd	Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.
US8589541B2 (en)	2009-01-28	2013-11-19	Headwater Partners I Llc	Device-assisted services for protecting network capacity
US20100192207A1 (en)	2009-01-28	2010-07-29	Gregory G. Raleigh	Virtual service provider systems
US12166596B2 (en)	2009-01-28	2024-12-10	Disney Enterprises, Inc.	Device-assisted services for protecting network capacity
US11985155B2 (en)	2009-01-28	2024-05-14	Headwater Research Llc	Communications device with secure data path processing agents
CN103561771B (zh)	2011-03-17	2019-01-04	伯明翰大学	重新定向的免疫治疗
EP3557260B1 (en)	2012-12-21	2022-05-18	Chugai Seiyaku Kabushiki Kaisha	Gpc3-targeting drug which is administered to patient responsive to gpc3-targeting drug therapy
TWI693073B (zh)	2012-12-21	2020-05-11	日商中外製藥股份有限公司	對ｇｐｃ３標的治療劑療法為有效之患者投與的ｇｐｃ３標的治療劑
WO2015109265A1 (en) *	2014-01-16	2015-07-23	Calysta, Inc.	Microorganisms for the enhanced production of amino acids and related methods
KR102409014B1 (ko)	2014-05-08	2022-06-14	추가이 세이야쿠 가부시키가이샤	Gpc3 표적 치료제 요법이 유효한 환자에게 투여되는 gpc3 표적 치료제
MA40764A (fr)	2014-09-26	2017-08-01	Chugai Pharmaceutical Co Ltd	Agent thérapeutique induisant une cytotoxicité
US11376326B2 (en)	2015-07-01	2022-07-05	Chugai Seiyaku Kabushiki Kaisha	GPC3-targeting therapeutic agent which is administered to patient for whom the GPC3-targeting therapeutic agent is effective
BR112018002386A8 (pt) *	2015-08-03	2022-10-18	Carsgen Therapeutics Ltd	Anticorpo contra glypican-3 e aplicação do mesmo
KR101796688B1 (ko) *	2015-10-29	2017-12-01	재단법인 목암생명과학연구소	신규 항-글리피칸 3 항체 및 이를 포함하는 약학적 조성물
AU2017212484C1 (en)	2016-01-27	2020-11-05	Medimmune, Llc	Methods for preparing antibodies with a defined glycosylation pattern
TW202248213A (zh)	2016-03-15	2022-12-16	日商中外製藥股份有限公司	使用pd-1軸結合拮抗劑和抗gpc3抗體治療癌症的方法
CA3031846A1 (en)	2016-07-26	2018-02-01	Tessa Therapeutics Pte. Ltd.	Chimeric antigen receptor
WO2018038046A1 (ja)	2016-08-22	2018-03-01	中外製薬株式会社	ヒトｇｐｃ３ポリペプチドを発現する遺伝子改変非ヒト動物
CN106591371A (zh) *	2016-11-25	2017-04-26	哈尔滨百伊生生物科技有限公司	Cd16a/gpc3双抗慢病毒表达载体及其构建方法和应用
WO2019059411A1 (en)	2017-09-20	2019-03-28	Chugai Seiyaku Kabushiki Kaisha	DOSAGE FOR POLYTHERAPY USING PD-1 AXIS BINDING ANTAGONISTS AND GPC3 TARGETING AGENT
EP3860716A2 (en)	2018-10-01	2021-08-11	Adicet Bio Inc.	Compositions and methods regarding engineered and non-engineered gamma-delta -t cells for treatment of solid tumors
KR20210105890A (ko)	2018-12-17	2021-08-27	레비토프 리미티드	트윈 면역 세포 인게이저
WO2020242950A1 (en) *	2019-05-24	2020-12-03	Elixiron Immunotherapeutics (hong Kong) Limited	Anti-csf1r antibodies, il10 fusion proteins, and uses thereof
MX2021014433A (es)	2019-06-05	2022-03-11	Chugai Pharmaceutical Co Ltd	Molecula de union a sitio de escision de anticuerpo.
US20240301085A1 (en) *	2021-02-10	2024-09-12	Simcere Zaiming Pharmaceutical Co., Ltd.	Humanized gpc3 antibody and application thereof

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPH0242355A (ja)	1988-08-02	1990-02-13	Hitachi Constr Mach Co Ltd	超音波検査装置
US5530101A (en) *	1988-12-28	1996-06-25	Protein Design Labs, Inc.	Humanized immunoglobulins
JPH04336051A (ja)	1991-05-10	1992-11-24	Toshiba Corp	超音波診断装置
AU4116793A (en)	1992-04-24	1993-11-29	Board Of Regents, The University Of Texas System	Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5622701A (en) *	1994-06-14	1997-04-22	Protein Design Labs, Inc.	Cross-reacting monoclonal antibodies specific for E- and P-selectin
WO1998023289A1 (en)	1996-11-27	1998-06-04	The General Hospital Corporation	MODULATION OF IgG BINDING TO FcRn
KR100655979B1 (ko) *	1997-02-12	2006-12-08	츄가이 세이야꾸 가부시키가이샤	임파구계 종양의 치료제
US7361336B1 (en) *	1997-09-18	2008-04-22	Ivan Bergstein	Methods of cancer therapy targeted against a cancer stem line
AU750453B2 (en) *	1997-10-03	2002-07-18	Chugai Seiyaku Kabushiki Kaisha	Natural human antibody
JPH11118775A (ja)	1997-10-09	1999-04-30	Canon Inc	超音波検査装置
US6528624B1 (en) *	1998-04-02	2003-03-04	Genentech, Inc.	Polypeptide variants
US20030175884A1 (en) *	2001-08-03	2003-09-18	Pablo Umana	Antibody glycosylation variants having increased antibody-dependent cellular cytotoxicity
JP4334141B2 (ja)	1998-04-20	2009-09-30	グリカートバイオテクノロジーアクチェンゲゼルシャフト	抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作
US6737056B1 (en) *	1999-01-15	2004-05-18	Genentech, Inc.	Polypeptide variants with altered effector function
EP2270149B1 (en) *	1999-04-09	2016-03-23	Kyowa Hakko Kirin Co., Ltd.	Method for controlling the activity of immunologically functional molecule
JP3606132B2 (ja)	1999-10-14	2005-01-05	Ｊｆｅエンジニアリング株式会社	超音波探傷方法およびその装置
JP2002048867A (ja)	2000-08-07	2002-02-15	Mitsubishi Heavy Ind Ltd	音響探査装置
WO2002022739A1 (en)	2000-09-12	2002-03-21	Union Carbide Chemicals & Plastics	Polymer composites containing alkylene oxide copolymers
JP4290423B2 (ja) *	2000-10-06	2009-07-08	協和発酵キリン株式会社	抗体組成物を生産する細胞
JP4336051B2 (ja)	2001-01-31	2009-09-30	株式会社エヌ・ティ・ティ・ドコモ	無線通信端末、発呼制限方法及びプログラム
US20030003097A1 (en)	2001-04-02	2003-01-02	Idec Pharmaceutical Corporation	Recombinant antibodies coexpressed with GnTIII
ATE483801T1 (de) *	2001-06-22	2010-10-15	Chugai Pharmaceutical Co Ltd	Zellproliferationshemmer, die anti-glypican 3 antikörper enthalten
JP3961359B2 (ja)	2002-07-18	2007-08-22	株式会社東芝	超音波画像化装置
JP4087098B2 (ja)	2001-11-14	2008-05-14	株式会社東芝	超音波検査装置
US7421900B2 (en) *	2001-11-14	2008-09-09	Kabushiki Kaisha Toshiba	Ultrasonograph, ultrasonic transducer, examining instrument, and ultrasonographing device
EP3604523A1 (en) *	2001-12-28	2020-02-05	Chugai Seiyaku Kabushiki Kaisha	Method for stabilizing proteins
US20040132101A1 (en) *	2002-09-27	2004-07-08	Xencor	Optimized Fc variants and methods for their generation
US20040110226A1 (en)	2002-03-01	2004-06-10	Xencor	Antibody optimization
US7317091B2 (en) *	2002-03-01	2008-01-08	Xencor, Inc.	Optimized Fc variants
US8188231B2 (en) *	2002-09-27	2012-05-29	Xencor, Inc.	Optimized FC variants
US7662925B2 (en) *	2002-03-01	2010-02-16	Xencor, Inc.	Optimized Fc variants and methods for their generation
AU2003236018A1 (en)	2002-04-09	2003-10-20	Kyowa Hakko Kirin Co., Ltd.	METHOD OF ENHANCING ACTIVITY OF ANTIBODY COMPOSITION OF BINDING TO FcGamma RECEPTOR IIIa
WO2004022597A1 (ja)	2002-09-04	2004-03-18	Chugai Seiyaku Kabushiki Kaisha	Gpc3の血中可溶化ｎ端ﾍﾟﾌﾟﾁﾄﾞに対する抗体
JP4455324B2 (ja) *	2002-05-23	2010-04-21	サニーブルックヘルスサイエンスセンター	肝細胞癌の診断
JP4406607B2 (ja)	2002-08-26	2010-02-03	オンコセラピー・サイエンス株式会社	ペプチド及びこれを含む医薬
AU2002328429A1 (en)	2002-09-04	2004-03-29	Chugai Seiyaku Kabushiki Kaisha	CONSTRUCTION OF ANTIBODY USING MRL/lpr MOUSE
WO2004023145A1 (ja)	2002-09-04	2004-03-18	Perseus Proteomics Inc.	Ｇｐｃ3の検出による癌の診断方法
US20090010920A1 (en) *	2003-03-03	2009-01-08	Xencor, Inc.	Fc Variants Having Decreased Affinity for FcyRIIb
JPWO2005023301A1 (ja) *	2003-09-04	2006-11-02	中外製薬株式会社	胆管癌治療剤および検出薬
ITBO20040008U1 (it)	2004-02-03	2004-05-03	Tonazzi S R L	Macchina per il riempimento e la chiusura di tubetti
NZ579543A (en) *	2004-07-09	2011-07-29	Chugai Pharmaceutical Co Ltd	Anti-glypican 3 antibody
DE602005024147D1 (de) *	2004-08-08	2010-11-25	Eli Khayat	Pharmazeutische zusammensetzungen zur linderung von übermässig hohen zuckerspiegeln bei diabetikern
WO2006023420A2 (en) *	2004-08-16	2006-03-02	Medimmune, Inc.	Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity
PL1800693T3 (pl)	2004-08-24	2013-12-31	Chugai Pharmaceutical Co Ltd	Terapia adiuwantowa z zastosowaniem przeciwciała przeciw glipikanowi 3
EP1816140A4 (en)	2004-10-26	2009-09-02	Chugai Pharmaceutical Co Ltd	ANTI-GLYPICAN ANTIBODY 3 MODIFIED SWEET CHAIN
JPWO2006067847A1 (ja) *	2004-12-22	2008-06-12	中外製薬株式会社	フコーストランスポーターの機能が阻害された細胞を用いた抗体の作製方法
US20070087005A1 (en)	2005-10-14	2007-04-19	Lazar Gregory A	Anti-glypican-3 antibody
MX369784B (es) *	2007-09-26	2019-11-21	Chugai Pharmaceutical Co Ltd	Metodo de modificacion del punto isoelectrico de anticuerpos mediante la sustitucion de aminoacidos en region de determinacion de complementariedad (cdr).
BRPI0909672B1 (pt) *	2008-03-17	2018-09-18	Chugai Pharmaceutical Co Ltd	método de imunoensaio in vitro para detecção da presença de células de câncer de fígado em um indivíduo, método para classificação de células de câncer de fígado presentes em um indivíduo, método in vitro para determinação de administrar ou não um agente anticâncer contendo um anticorpo anti-glipicano 3 a um indivíduo, e método in vitro para determinação de uma dose de um agente anticâncer contendo um anticorpo anti-glipicano 3 no tratamento de câncer de fígado em um indivíduo
CL2009000647A1 (es) *	2008-04-04	2010-06-04	Chugai Pharmaceutical Co Ltd	Composicion farmaceutica para tratar o prevenir cancer hepatico que comprende una combinacion de un agente quimioterapeutico y un anticuerpo anti-glipicano 3; agente para atenuar un efecto secundario que comprende dicho anticuerpo; metodo para tratar o prevenir un cancer hepatico de un sujeto.

2005
- 2005-10-26 EP EP05800031A patent/EP1816140A4/en not_active Ceased
- 2005-10-26 UA UAA200705812A patent/UA93488C2/uk unknown
- 2005-10-26 JP JP2006542382A patent/JP4794457B2/ja not_active Expired - Fee Related
- 2005-10-26 TW TW94137496A patent/TWI468514B/zh not_active IP Right Cessation
- 2005-10-26 WO PCT/JP2005/020057 patent/WO2006046751A1/ja active Application Filing
- 2005-10-26 CN CN2005800368760A patent/CN101068836B/zh not_active Expired - Fee Related
- 2005-10-26 KR KR1020077011403A patent/KR101296931B1/ko not_active Expired - Fee Related
- 2005-10-26 BR BRPI0518279-4A patent/BRPI0518279A2/pt not_active IP Right Cessation
- 2005-10-26 RU RU2007119579/10A patent/RU2451030C2/ru not_active IP Right Cessation
- 2005-10-26 US US11/577,944 patent/US7867734B2/en not_active Expired - Fee Related
- 2005-10-26 NZ NZ554940A patent/NZ554940A/en not_active IP Right Cessation
- 2005-10-26 CA CA2585196A patent/CA2585196C/en not_active Expired - Fee Related
- 2005-10-26 MX MX2007004593A patent/MX2007004593A/es active IP Right Grant
- 2005-10-26 AU AU2005297772A patent/AU2005297772B2/en not_active Ceased
2007
- 2007-04-19 IL IL182662A patent/IL182662A/en not_active IP Right Cessation
- 2007-05-09 NO NO20072366A patent/NO20072366L/no not_active Application Discontinuation
- 2007-05-14 ZA ZA200703888A patent/ZA200703888B/xx unknown
- 2007-05-17 MA MA29912A patent/MA29025B1/fr unknown
- 2007-05-25 CR CR9151A patent/CR9151A/es not_active Application Discontinuation
2008
- 2008-04-23 HK HK08104536.5A patent/HK1110335A1/xx not_active IP Right Cessation
2010
- 2010-08-09 US US12/852,950 patent/US20110033452A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20080124330A1 (en)	2008-05-29
RU2451030C2 (ru)	2012-05-20
TW200621980A (en)	2006-07-01
KR20070070222A (ko)	2007-07-03
AU2005297772A1 (en)	2006-05-04
UA93488C2 (uk)	2011-02-25
EP1816140A1 (en)	2007-08-08
CN101068836B (zh)	2013-08-14
EP1816140A4 (en)	2009-09-02
MA29025B1 (fr)	2007-11-01
RU2007119579A (ru)	2008-12-10
US20110033452A1 (en)	2011-02-10
IL182662A0 (en)	2007-09-20
WO2006046751A1 (ja)	2006-05-04
JPWO2006046751A1 (ja)	2008-05-22
NO20072366L (no)	2007-06-21
MX2007004593A (es)	2007-06-22
IL182662A (en)	2014-09-30
CA2585196A1 (en)	2006-05-04
BRPI0518279A2 (pt)	2008-11-11
NZ554940A (en)	2010-04-30
TWI468514B (zh)	2015-01-11
KR101296931B1 (ko)	2013-08-14
CN101068836A (zh)	2007-11-07
CA2585196C (en)	2015-01-06
CR9151A (es)	2008-03-18
JP4794457B2 (ja)	2011-10-19
HK1110335A1 (en)	2008-07-11
AU2005297772B2 (en)	2011-06-23
US7867734B2 (en)	2011-01-11

Publication	Publication Date	Title
ZA200703888B (en)	2009-11-25	Anti-glypican 3 antibody having modified sugar chain
GB0228210D0 (en)	2003-01-08	Single chain antibodies
PT1599504E (pt)	2015-03-02	Anticorpo modificado
IL227753A0 (en)	2013-09-30	A qualified antibody or antibody residue
HK1218126A1 (zh)	2017-02-03	抗體
IL181575A0 (en)	2007-07-04	Anti-ox40l antibodies
IL228032A0 (en)	2013-09-30	Antibodies
IL175710A0 (en)	2006-09-05	Anti-mpl antibody
IL179672A0 (en)	2007-05-15	Anti-cd3 antibodies
IL187316A0 (en)	2008-04-13	Anti-interleukin 2 antibodies
HK1093873A1 (en)	2007-03-16	Slide fastener chain
IL187106A (en)	2015-10-29	Sclerostin binds antibody
IL190472A0 (en)	2008-11-03	Anti-glypican-3 antibody
IL185366A0 (en)	2008-02-09	Antibody
HK1084839A1 (en)	2006-08-11	Bracelet fastener
GB0420466D0 (en)	2004-10-20	Anti-glucan antibodies
GB2420392B (en)	2009-05-06	Silent chain
ZA200701952B (en)	2008-10-29	Anti-OX40L antibodies
GB0306618D0 (en)	2003-04-30	Antibody
GB2417997B (en)	2008-12-24	Link chain
EP1780221A4 (en)	2007-10-03	ANTI-SYNOVIOLIN ANTIBODY
GB0418415D0 (en)	2004-09-22	Antibody
GB0420771D0 (en)	2004-10-20	Antibody
HK1209139A1 (en)	2016-03-24	Modified antibody
GB0417434D0 (en)	2004-09-08	Adaptable necklace